Shining a light on Alzheimer's: new combo therapy trial
NCT ID NCT06992804
Summary
This study is testing whether adding a special near-infrared light therapy to the approved Alzheimer's drug lecanemab is safe and more effective at controlling the disease. It will involve 20 people with mild Alzheimer's. For 16 weeks, half will get the real light therapy with the drug, while the other half gets a fake light device with the drug, followed by a longer phase where everyone gets the real treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuanwu Hospital, Capital Medical University
RECRUITINGBeijing, 100053, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.